ImmuPharma PLC LON:IMM this week released their annual report for the year ending 31st December 2014. In it, they report on a number of exciting developments for the Company.
Post-period end, an agreement was reached with Simbec-Orion, an international clinical research organisation, to begin the pivotal Phase III clinical trial for Lupuzor (TM). Also announced was that the Phase I/IIa trial of their cancer program has been completed and further therapeutic applications have been identified. In October, their French subsidiary, Ureka sarl, was awarded a grant of approximately €400,000 to develop its proprietary UrelixTM technology.
Further, the Company concluded a successful share placement that month resulting in gross proceeds to the Company of approximately £3.4 million. In January 2015, the Company received advance assurance from HMRC (the UK tax authorities) that it would qualify for Enterprise Investment Scheme status.
ImmuPharma PLC LON:IMM is a pharmaceutical company, focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. They have five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation.